Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 13:58:52 - browse：3355

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Private equity deals in Medicare Advantage declines

focus

WSS

Here's how to stay safe from wildfire smoke amid reduced air quality

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

ADA: All diabetes patients should be screened for liver condition

What we’ve learned from the Aduhelm mess

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Readout LOUD podcast: How biotech is using artificial intelligence

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

For Medicare Advantage, Democrats want stronger protections around AI

FDA approval of Sarepta Duchenne genetic therapy gives me hope

PhRMA lawsuit over Medicare drug price negotiation tossed

Peter Hotez and the public health issue of online harassment

Supreme Court strikes down Biden student loan forgiveness program

Medicare details structure of new drug price negotiation program

What we’ve learned from the Aduhelm mess

Psychedelics group wrestles with new pharma identity

For Medicare Advantage, Democrats want stronger protections around AI

explore

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Robert F. Kennedy is pitching centrism on health, even on abortion

What should King Charles tell the public about his cancer?

Doctors' information doesn't help them choose wisely when sick

Private equity deals in Medicare Advantage declines

Vaccine advisory panel ACIP left half staffed by HHS

focus

focus

focus

explore